Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblasti...(attacks. Thesecytolytic synapses enable ...),Health

Date:10/18/2007

attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target tumor cells. Through the process of killing cancer cells, T cells proliferate, which leads to an increased number of T cells at the site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE product development platform. The most advanced BiTE antibody is MT103 (MEDI-538), targeting CD19, which has provided proof-of-concept in an ongoing phase 1 clinical study in advanced non-Hodgkin's lymphoma patients. Three other BiTE antibodies, targeting EpCAM (CD326), CEA and MCSP, are in pre-clinical development.

About MT103 (MEDI-538)

MT103, which is being co-developed with MedImmune as MEDI-538, is a BiTE(R) antibody being developed with the intent to treat patients with certain types of B-cell lymphomas. MT103 received orphan drug designation from the EMEA for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. In February 2006, the U.S. Food and Drug Administration (FDA) also approved an orphan drug designation for MT103 for the treatment of certain indolent B-cell lymphomas. MT103 specifically targets the CD19 antigen, which is present on B-cells and B cell-derived tumors but not on other types of blood cells or healthy tissues.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its a
'/>"/>

SOURCE Micromet, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Infant receives first bloodless liver transplant
2. British MPs Say Prostate Cancer Receives Low Priority in the NHS
3. Fifth US Patient Receives Artificial Heart
4. Northfield Labs Receives FDA Comments
5. Abbott Receives CE Mark Certification
6. Zactima Receives Fast Track Designation By The FDA
7. East London Receives World Class New Private Hospital Facility
8. Brinda Karat Receives Legal Notice over Ramdev Issue
9. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
10. Medtronic’s Insulin Pump Receives Regulatory Approva
11. Aurobindo Receives Approval from USFDA for anti-AIDS drug